As part of our commitment to supporting cancer patients and to research, we are inviting you to take part in the European Cancer Patient Coalition (ECPC) Survey on biomarker testing. The survey, translated into 13 languages, can be taken until August 15th 2020 with this link. You can choose the language you wish to take the survey in by using the drop-down menu provided at the beginning of the survey.
This second survey, four years after the first, and with a great number of newer biomarkers and new cancer medicines available, will help to better understand the knowledge about biomarkers and the experiences you as cancer patients and survivors had during your diagnosis and, in particular, during biomarker testing, if you had such.
You can find the survey here:

The ECPC is particularly looking for patients from the UK to complete the survey but all are welcome to take part.

What are biomarkers?

A biomarker is a molecule or a gene, the presence or absence of which can be used to characterise a particular cancer type. Biomarkers are typically tested for in order to help physicians choose the right therapy, depending on the patient’s genetic profile (e.g., in breast cancer, whether or not a breast cancer patient tests positive for HER2 can inform if the drug Trastuzumab is appropriate/suitable for the patient). Biomarker testing may also be called “molecular testing” or “genetic testing” in clinical practice with the same meaning.¹

For appendix cancer patients, whether the patient tests positive for KRAS can inform if the drug AMG 510 may be appropriate/suitable for the patient.

¹ECPC website, retrieved 22nd July 2020